Investor Ideas Adds New Nasdaq Stocks in Biotech- $RLAY, $IVA, $NKTX, $PSTX

 

Investor Ideas Adds New Nasdaq Stocks in Biotech- $RLAY, $IVA, $NKTX, $PSTX

 

New CSE Stocks in Mining (CSE: $CC.C) (CSE: $LIDO.C)

 

 

 

 

 

 

 

 

 

 

 

Point Roberts WA, Delta BC, July 31, 2020 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor resource announces its weekly roundup of stocks added to its global stock directories, including biotech and mining.

 

Read this in full at https://www.investorideas.com/news/2020/main/07311Stocks.asp

 

This week’s new biotech companies are all Nasdaq IPOs from July.

 

The latest mining companies are new listings from the CSE (Canadian Stock Exchange).

 

New Stocks added to Biotech stocks directory

Relay Therapeutics, Inc. (NasdaqGS:RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, Relay Therapeutics aims to effectively drug protein targets that have previously been intractable, with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company’s Dynamo platform integrates an array of leading-edge experimental and computational approaches to provide a differentiated understanding of protein structure and motion to drug these targets.

 

Inventiva S.A. (NasdaqGM:IVA)  is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs. Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH. Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. A Phase I/II clinical trial in children with MPS VI is currently under preparation following the release of positive results of the Phase IIa clinical trial in adult MPS VI patients at the end of 2019. In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.

 

Nkarta, Inc. (NasdaqGS:NKTX) focuses on combining its natural killer (NK) cell expansion and cryopreservation platform with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkarta’s mission is to discover, develop and deliver novel off-the-shelf NK cell therapy product candidates that have a profound impact on patients.

 

Poseida Therapeutics, Inc. (NasdaqGS:PSTX) is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Modification System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.

 

New Stocks added to Mining stocks directory

Core Assets Corp. (CSE:CC)  is focused on the global acquisition, exploration, development and mining of mineral properties. The company's current focus is the exploration and development of the Blue Property, located 48 km SW of Atlin, BC which is believed to be prospective for copper, cobalt, silver and gold.

 

Lido Minerals Ltd. (CSE:LIDO) is a Canadian based mineral exploration company, actively involved the exploration of the Nimpkish properties on Vancouver Island

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.

We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.      

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 

 

 

 

 

 

 

Patriot One (TSX: $PAT.TO) (OTCQX: $PTOTF) @patriot1tech Reports Subsidiary Xtract #AI division reports new project contract with Canexia Health; #Artificialintelligence

Patriot One (TSX: $PAT.TO) (OTCQX: $PTOTF) @patriot1tech Reports Subsidiary Xtract #AI division reports new project contract with Canexia Health; #Artificialintelligence

Project ACTT (Access to Cancer Testing & Treatment in Response to COVID-19) aims to provide a liquid biopsy solution, that requires only a simple blood draw, as an alternative to surgical tissue biopsies

VANCOUVER, BC – JULY 16, 2020  – Investorideas.com Newswire and Homelanddefensestocks.com –Security/Covid -19/AI stock news -Patriot One Technologies Inc. (TSX: PAT) (OTCQX: PTOTF), (FRANKFURT: 0PL) wholly-owned subsidiary Xtract Technologies Inc. (“Xtract AI”)  is pleased to announce a new project contract with Canexia Health (formerly Contextual Genomics) and supported by the Digital Technology Supercluster.

Read this news featuring Patriot One in full at https://www.investorideas.com/news/2020/defense/07161PatriotOne-CanexiaHealth.asp

As the COVID-19 pandemic has impacted many areas of life, including the diagnosis and treatment of other health conditions, people have chosen to forgo care in attempts to minimize their potential exposure to the Coronavirus. Cancer patients are twice as likely to contract COVID-19, and three times as likely to die from it, compared to the general population. However, by avoiding time spent in medical facilities to limit exposure to the virus, patients are delaying treatment and their disease may spread further. At least 100,000 surgeries in Canada, including cancer tissue biopsies, have been delayed or postponed since early March because of COVID-19.

Project ACTT (Access to Cancer Testing & Treatment in Response to COVID-19) aims to provide a liquid biopsy solution, that requires only a simple blood draw, as an alternative to surgical tissue biopsies. This minimally invasive DNA test, which can be delivered remotely, will then be analyzed by artificial intelligence technology to identify circulating tumor DNA (ctDNA) in plasma, and matches patients with targeted treatments shown to improve outcomes. Not only will this reduce a patient’s need to attend medical facilities, it will also increase health system capacity for those with recurrent or metastatic lung, breast, or colon cancer.

Other partners in the project include AstraZeneca Canada, Queen’s University, the Eastern Ontario Regional Laboratory Association, Genolife, emtelligent, Novateur, Semaphore Solutions and Illumina. Xtract AI will develop, train, and deploy Natural Language Processing (NLP) models to assist in the management, understanding, and integration of semi-structured information from a mutation and cancer-type database.

Martin Cronin, Patriot One Technologies CEO, said “knowing how far reaching the effects of COVID-19 are, we’re delighted to be involved in another project utilizing artificial intelligence, and our team’s expertise, in an effort to significantly, and hopefully positively, impact the lives of cancer patients.”

About XTRACT TECHNOLOGIES INC - a subsidiary of Patriot One Technologies Inc.

Xtract AI develops and commercializes artificial intelligence, machine learning, deep neural networks and predictive solutions utilizing advanced technology for public institutions and private enterprise. The firm has an award winning, highly skilled team that develops AI solutions to solve challenges across computer vision (CV), natural language processing (NLP), anomaly detection, and time-series analysis for applications ranging from security and defence to environmental solutions and healthcare. For more information on building your AI solution, visit: xtract.ai

About Patriot One Technologies Inc. (TSX:PAT) (OTCQX: PTOTF) (FRA: 0PL):

Patriot Ones' mission is to deliver innovative threat detection and counter-terrorism solutions for safer communities. Our PATSCAN™ Multi-Sensor Covert Threat Detection Platform provides a network of advanced sensor technologies with powerful next generation AI/machine learning software. The network can be covertly deployed from far perimeter to interiors across multiple weapons-restricted facilities. The PATSCAN™ platform identifies and reports threats wherever required; car park, building approach, employee & public entryways and inside the facilities. Each solution in the platform identifies weapons, related threats or disturbances, or potential health and safety threats for immediate security response. Our motto Deter, Detect and Defend is based on the belief that widespread use of the PATSCAN™ platform will act as an effective deterrent to diminish the epidemic of active threats around the globe. For more information, visit: www.patriot1tech.com or follow us on Twitter and Facebook.

About Digital Technology Supercluster:

The Digital Technology Supercluster solves some of industry’s and society’s biggest problems through Canadian-made technologies. We bring together private and public sector organizations of all sizes to address challenges facing Canada’s economic sectors including healthcare, natural resources, manufacturing, and transportation. Through this ‘collaborative innovation,’ the Supercluster helps to drive solutions better than any single organization could on its own.  The Digital Technology Supercluster is led by industry leaders such as D-Wave, LifeLabs, LlamaZOO, Lululemon, MDA, Microsoft, Mosaic Forest Management, Sanctuary AI, Teck Resources Limited, TELUS, Terramera, and 1Qbit. Together, we work to position Canada as a global hub for digital innovation. A full list of Members can be found here.

About the COVID-19 Program:

The COVID-19 Program aims to improve the health and safety of Canadians and support Canada’s ability to address issues created by the COVID-19 outbreak. In addition, the program will build expertise and capacity to anticipate and address issues that may arise in future health crises, from healthcare to a return to work and community. More information can be found here.

For further information, please contact:

Patriot One Technologies Inquiries
info@patriot1tech.com
www.patriot1tech.com

Investor Relations
John Martin, Patriot One Technologies
+1 (888) 728-1332
johnm@patriot1tech.com

                                                                               

Media Contacts
Scott Ledingham, Patriot One Technologies
+1-613-806-7135
scott@prmedianow.com    

             

For Digital Technology Supercluster Inquiries

Elysa Darling, Switchboard PR

1-587-890-9833

elysa@switchboardpr.com

                             

CAUTIONARY DISCLAIMER STATEMENT:

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to system sales, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects”,” believes”, and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include counterparty default and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by applicable law.

Neither the Toronto Stock Exchange (TSX) nor its Regulation Services Provider (as that term is defined in policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring TSX: PAT is a paid for news release on Investorideas.com ($750) More disclaimer info:

https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire

https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com

https://www.investorideas.com/About/

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

Get more Defense Stock Investor Ideas - news, articles, and stock directories

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

#Security/#Covid19/#AI #stock news -Patriot One’s (TSX: $PAT.TO) (OTCQX: $PTOTF) Xtract AI division working with Canexia Health to increase access to cancer testing; @patriot1tech #artificialintelligence

#Security/#Covid19/#AI #stock news -Patriot One’s (TSX: $PAT.TO) (OTCQX: $PTOTF) Xtract AI division working with Canexia Health to increase access to cancer testing; @patriot1tech #artificialintelligence

Vancouver-based AI firm to work on a Digital Technology Supercluster COVID-19 Program project

VANCOUVER, BC – JULY 15, 2020  –  Investorideas.com Newswire and Homelanddefensestocks.com –Security/Covid -19/AI stock news -Patriot One Technologies Inc. (TSX: PAT) (OTCQX: PTOTF), (FRANKFURT: 0PL) wholly-owned subsidiary Xtract Technologies Inc. (“Xtract AI”)  is pleased to announce a new project contract with Canexia Health (formerly Contextual Genomics) and supported by the Digital Technology Supercluster.

Read this news featuring Patriot One in full at https://www.investorideas.com/news/2020/defense/07151TSXPAT-CanexiaHealth.asp

As the COVID-19 pandemic has impacted many areas of life, including the diagnosis and treatment of other health conditions, people have chosen to forgo care in attempts to minimize their potential exposure to the Coronavirus. Cancer patients are twice as likely to contract COVID-19, and three times as likely to die from it, compared to the general population. However, by avoiding time spent in medical facilities to limit exposure to the virus, patients are delaying treatment and their disease may spread further. At least 100,000 surgeries in Canada, including cancer tissue biopsies, have been delayed or postponed since early March because of COVID-19.

Project ACTT (Access to Cancer Testing & Treatment in Response to COVID-19) aims to provide a liquid biopsy solution, that requires only a simple blood draw, as an alternative to surgical tissue biopsies. This minimally invasive DNA test, which can be delivered remotely, will then be analyzed by artificial intelligence technology to identify circulating tumor DNA (ctDNA) in plasma, and matches patients with targeted treatments shown to improve outcomes. Not only will this reduce a patient’s need to attend medical facilities, it will also increase health system capacity for those with recurrent or metastatic lung, breast, or colon cancer.

Other partners in the project include AstraZeneca Canada, Queen’s University, the Eastern Ontario Regional Laboratory Association, Genolife, emtelligent, Novateur, Semaphore Solutions and Illumina. Xtract AI will develop, train, and deploy Natural Language Processing (NLP) models to assist in the management, understanding, and integration of semi-structured information from a mutation and cancer-type database.

Martin Cronin, Patriot One Technologies CEO, said “knowing how far reaching the effects of COVID-19 are, we’re delighted to be involved in another project utilizing artificial intelligence, and our team’s expertise, in an effort to significantly, and hopefully positively, impact the lives of cancer patients.”

About XTRACT TECHNOLOGIES INC - a subsidiary of Patriot One Technologies Inc.

Xtract AI develops and commercializes artificial intelligence, machine learning, deep neural networks and predictive solutions utilizing advanced technology for public institutions and private enterprise. The firm has an award winning, highly skilled team that develops AI solutions to solve challenges across computer vision (CV), natural language processing (NLP), anomaly detection, and time-series analysis for applications ranging from security and defence to environmental solutions and healthcare. For more information on building your AI solution, visit: xtract.ai

About Patriot One Technologies Inc. (TSX:PAT) (OTCQX: PTOTF) (FRA: 0PL):

Patriot Ones' mission is to deliver innovative threat detection and counter-terrorism solutions for safer communities. Our PATSCAN™ Multi-Sensor Covert Threat Detection Platform provides a network of advanced sensor technologies with powerful next generation AI/machine learning software. The network can be covertly deployed from far perimeter to interiors across multiple weapons-restricted facilities. The PATSCAN™ platform identifies and reports threats wherever required; car park, building approach, employee & public entryways and inside the facilities. Each solution in the platform identifies weapons, related threats or disturbances, or potential health and safety threats for immediate security response. Our motto Deter, Detect and Defend is based on the belief that widespread use of the PATSCAN™ platform will act as an effective deterrent to diminish the epidemic of active threats around the globe. For more information, visit: www.patriot1tech.com or follow us on Twitter and Facebook.

About Digital Technology Supercluster:

The Digital Technology Supercluster solves some of industry’s and society’s biggest problems through Canadian-made technologies. We bring together private and public sector organizations of all sizes to address challenges facing Canada’s economic sectors including healthcare, natural resources, manufacturing, and transportation. Through this ‘collaborative innovation,’ the Supercluster helps to drive solutions better than any single organization could on its own.  The Digital Technology Supercluster is led by industry leaders such as D-Wave, LifeLabs, LlamaZOO, Lululemon, MDA, Microsoft, Mosaic Forest Management, Sanctuary AI, Teck Resources Limited, TELUS, Terramera, and 1Qbit. Together, we work to position Canada as a global hub for digital innovation. A full list of Members can be found here.

About the COVID-19 Program:

The COVID-19 Program aims to improve the health and safety of Canadians and support Canada’s ability to address issues created by the COVID-19 outbreak. In addition, the program will build expertise and capacity to anticipate and address issues that may arise in future health crises, from healthcare to a return to work and community. More information can be found here.

For further information, please contact:

Patriot One Technologies Inquiriesinfo@patriot1tech.com
www.patriot1tech.com

Investor RelationsJohn Martin, Patriot One Technologies
+1 (888) 728-1332 johnm@patriot1tech.com

                                                                               

Media ContactsScott Ledingham, Patriot One Technologies
+1-613-806-7135scott@prmedianow.com   

             

For Digital Technology Supercluster Inquiries

Elysa Darling, Switchboard PR

1-587-890-9833

elysa@switchboardpr.com

                             

CAUTIONARY DISCLAIMER STATEMENT:

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to system sales, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects”,” believes”, and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include counterparty default and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by applicable law.

Neither the Toronto Stock Exchange (TSX) nor its Regulation Services Provider (as that term is defined in policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring TSX: PAT is a paid for news release on Investorideas.com ($750) More disclaimer info:

https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire

https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com

https://www.investorideas.com/About/

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

Get more Defense Stock Investor Ideas - news, articles, and stock directories

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory